Table 5 Antimalarial activity of MCM-41 encapsulated ATS (3) in P. berghei NK65-infected mice.
From: Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance
Dose (mg/kg bw) | Parasitemia (% Reduction) | Mean Survival Time (Days) | ||
|---|---|---|---|---|
Day 4 post-inoculation | Day 6 post-inoculation | Day 8 post-inoculation | ||
Infected Untreated | 2.81 | 3.61 | 9.60 | 7.75 |
ATS3 (5) | 0.45(83.99) | 0.97(73.13) | 2.30(74.86) | 23.47 |
0.0625 | 1.55(44.84) | 0.82(77.28) | 0.28(96.94) | 13.01 |
0.125 | 1.88(33.10) | 1.40(61.22) | 1.55(83.06) | 11.01 |
0.25 | 0.12(95.73) | 1.61(55.29) | 0.09(98.97) | 16.30 |
0.50 | 0.30(89.32) | 1.70(55.40) | 0.09(98.97) | 12.33 |
1.00 | 0.59(79.00) | 0.27(92.52) | 0(100) | 11.50 |
